JP2020171316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020171316A5 JP2020171316A5 JP2020120557A JP2020120557A JP2020171316A5 JP 2020171316 A5 JP2020171316 A5 JP 2020171316A5 JP 2020120557 A JP2020120557 A JP 2020120557A JP 2020120557 A JP2020120557 A JP 2020120557A JP 2020171316 A5 JP2020171316 A5 JP 2020171316A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- disease
- dermatomyositis
- composition
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 201000001981 dermatomyositis Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 7
- 230000004927 fusion Effects 0.000 claims 7
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000005987 polymyositis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108010091326 Cryoglobulins Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000003862 health status Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 238000002278 reconstructive surgery Methods 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500795P | 2011-06-24 | 2011-06-24 | |
| US61/500,795 | 2011-06-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019012303A Division JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020171316A JP2020171316A (ja) | 2020-10-22 |
| JP2020171316A5 true JP2020171316A5 (cg-RX-API-DMAC7.html) | 2021-06-10 |
Family
ID=47423247
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517226A Expired - Fee Related JP6216921B2 (ja) | 2011-06-24 | 2012-06-22 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2016246746A Withdrawn JP2017079769A (ja) | 2011-06-24 | 2016-12-20 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2019012303A Pending JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2020120557A Pending JP2020171316A (ja) | 2011-06-24 | 2020-07-14 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517226A Expired - Fee Related JP6216921B2 (ja) | 2011-06-24 | 2012-06-22 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2016246746A Withdrawn JP2017079769A (ja) | 2011-06-24 | 2016-12-20 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
| JP2019012303A Pending JP2019058197A (ja) | 2011-06-24 | 2019-01-28 | アルファ−１抗トリプシン融合分子のための組成物、方法および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9938353B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3628327A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6216921B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102103476B1 (cg-RX-API-DMAC7.html) |
| AU (4) | AU2012272636A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2839917A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012178102A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| KR102103476B1 (ko) * | 2011-06-24 | 2020-04-23 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| EP3569243A1 (en) * | 2011-06-28 | 2019-11-20 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
| WO2013106589A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| EP2978442B1 (en) | 2013-03-29 | 2020-03-18 | The Regents of the University of Colorado, a body corporate | Alpha 1 antitrypsin of use for preparing a subject for transplant |
| US10300119B2 (en) | 2013-05-15 | 2019-05-28 | Mor Research Applications Ltd. | Compositions and methods for preventing injury during or resulting from cardiac surgery |
| US20160194365A1 (en) | 2013-07-08 | 2016-07-07 | The University Of Utah Research Foundation | Methods for treatment of and prophylaxis against inflammatory disorders |
| JP6372562B2 (ja) * | 2014-03-19 | 2018-08-15 | 株式会社安川電機 | 回転電機 |
| US20170190762A1 (en) * | 2014-06-11 | 2017-07-06 | Beth Israel Deaconess Medical Center, Inc. | Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases |
| WO2016144984A1 (en) * | 2015-03-10 | 2016-09-15 | Anvil Biosciences, Llc | Serpins for the treatment of neuroinflammatory diseases |
| IL268752B2 (en) * | 2017-02-21 | 2024-01-01 | Kamada Ltd | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| HRP20240475T8 (hr) * | 2017-12-01 | 2024-08-02 | Csl Behring Llc | A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica |
| CN112839964A (zh) * | 2018-06-07 | 2021-05-25 | 普泰公司 | 包含融合蛋白的药物组合物及其用途 |
| CN109251936B (zh) * | 2018-09-20 | 2021-09-10 | 四川理工学院 | 一种光滑鳖甲丝氨酸蛋白酶抑制剂融合蛋白及制备与应用 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| JP2023513018A (ja) * | 2020-01-30 | 2023-03-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ－１アンチトリプシン欠乏症の治療方法 |
| WO2021178448A1 (en) * | 2020-03-02 | 2021-09-10 | Motor Life Sciences, Llc | Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity |
| AU2021248641A1 (en) | 2020-04-03 | 2022-10-27 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| KR102689456B1 (ko) * | 2020-11-16 | 2024-07-29 | 경북대학교 산학협력단 | 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물 |
| EP4507720A1 (en) * | 2022-04-14 | 2025-02-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections |
| EP4480493A1 (en) | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung |
| WO2024261171A1 (en) * | 2023-06-22 | 2024-12-26 | Aatec Medical Gmbh | Recombinant aat from yeast to treat transplants |
| WO2025014986A2 (en) * | 2023-07-10 | 2025-01-16 | Precigen, Inc. | Therapy for alpha-1 antitrypsin deficiency |
| KR20250076724A (ko) * | 2023-11-22 | 2025-05-30 | 아주대학교산학협력단 | 지속형 재조합 알파-1 항트립신 및 이의 용도 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| GB1472700A (en) | 1974-11-01 | 1977-05-04 | Ono Pharmaceutical Co | Guanidinobehzoic acid derivatives and process for preparing the same |
| JPS5470241A (en) | 1977-11-09 | 1979-06-05 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivative and its preparation |
| GB2044760B (en) | 1979-03-01 | 1983-03-23 | Ono Pharmaceutical Co | Guanidinobenzoic acid derivatives |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU577259B2 (en) | 1982-08-13 | 1988-09-22 | Zymogenetics Inc. | Glycolytic promters for regulated protein expression protease inhibitor |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| WO1986000337A1 (fr) | 1984-06-19 | 1986-01-16 | Transgene S.A. | DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION |
| US4629567A (en) | 1986-03-07 | 1986-12-16 | Smithkline-Rit | Alpha-1-antiprotease purification |
| US5157019A (en) | 1986-03-18 | 1992-10-20 | Monsanto Company | Serine protease inhibitors |
| US4829052A (en) | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
| US5008242A (en) | 1986-12-24 | 1991-04-16 | John Lezdey | Treatment of inflammation using 1-antichymotrypsin |
| US5093316A (en) | 1986-12-24 | 1992-03-03 | John Lezdey | Treatment of inflammation |
| US4829054A (en) | 1987-04-13 | 1989-05-09 | Miles Laboratories, Inc. | Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia |
| US4857538A (en) | 1987-11-30 | 1989-08-15 | The Research Foundation Of State University Of New York | New compounds for the study and treatment of microfilament organization in cells |
| US4963654A (en) | 1989-02-13 | 1990-10-16 | Taisho Pharmaceutical Co., Ltd. | Peptide serine protease inhibitor |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| US5612194A (en) | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
| JP2568281B2 (ja) | 1989-11-17 | 1996-12-25 | 原田工業株式会社 | 自動車用三波共用アンテナ |
| US5714140A (en) | 1989-12-13 | 1998-02-03 | Otsuka Pharmaceutical Co., Ltd. | Method for inhibiting the production of bioactive IL-1 by administering M-CSF |
| ATE146970T1 (de) | 1990-10-16 | 1997-01-15 | John Lezdey | Behandlung von entzündungen |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| US5470970A (en) | 1991-02-28 | 1995-11-28 | Dana-Farber Cancer Institute, Inc. | Maspin, a serpin with tumor suppresing activity |
| WO1992018141A1 (en) | 1991-04-18 | 1992-10-29 | The Uab Research Foundation | Compositions and methods for inhibiting elastase |
| US5175253A (en) | 1991-04-24 | 1992-12-29 | Washington University | Binding peptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5216022A (en) | 1991-12-19 | 1993-06-01 | Cortech, Inc. | Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase |
| EP0670737A4 (en) | 1992-03-26 | 1996-05-29 | Gensia Inc | IN VIVO PEPTIDE THERAPY. |
| GB9209032D0 (en) * | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
| US5734014A (en) | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
| US5376633A (en) | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
| US5604201A (en) | 1993-01-08 | 1997-02-18 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | Methods and reagents for inhibiting furin endoprotease |
| US5346886A (en) | 1993-11-15 | 1994-09-13 | John Lezdey | Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin |
| JPH0827371A (ja) | 1994-05-09 | 1996-01-30 | Japan Carlit Co Ltd:The | 紫外線及び赤外線吸収樹脂組成物 |
| US6090786A (en) | 1994-06-10 | 2000-07-18 | Fondatech Benelux N.V. | Serine proteases, their activity and their synthetic inhibitors |
| US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
| US5514653A (en) | 1994-09-09 | 1996-05-07 | Washington University | Method of blocking the SEC receptor |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| US5712117A (en) | 1995-02-08 | 1998-01-27 | Zymogenetics, Inc. | Cytoplasmic antiproteinase-2 and coding sequences |
| ATE377006T1 (de) | 1995-11-28 | 2007-11-15 | Cephalon Inc | Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer |
| US6136834A (en) | 1995-12-27 | 2000-10-24 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds and pharmaceutical agents containing such derivative |
| KR100356956B1 (ko) | 1996-03-11 | 2003-03-15 | 베이어 코오포레이숀 | 사람비쿠닌 |
| US6072041A (en) | 1996-06-03 | 2000-06-06 | Case Western Reserve University | Fusion proteins for protein delivery |
| US5780440A (en) | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| US5616693A (en) | 1996-07-01 | 1997-04-01 | Alpha Therapeutic Corporation | Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP0950067B1 (en) | 1996-11-27 | 2007-08-29 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| RU2217436C2 (ru) | 1996-12-06 | 2003-11-27 | Кортеч, Инк. | Производные оксадиазола, тиадиазола или триазола, являющиеся ингибиторами сериновых протеаз, и содержащие их фармацевтические композиции |
| US6150332A (en) * | 1997-01-09 | 2000-11-21 | Virginia Commonwealth University | Method and composition for lowering low density lipoprotein cholesterol |
| US6127145A (en) | 1997-02-13 | 2000-10-03 | Applied Phytologics, Inc. | Production of α1 -antitrypsin in plants |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| DE19735587B4 (de) | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
| US6124257A (en) | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
| US6964869B2 (en) | 1998-07-13 | 2005-11-15 | Wisconsin Alumni Research Foundation | Method and composition for skin grafts |
| US6197294B1 (en) | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| EP1150699A4 (en) | 1999-02-01 | 2004-06-30 | John Lezdey | TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS |
| GB9904421D0 (en) | 1999-02-25 | 1999-04-21 | Univ Edinburgh | Telecommunications receiver |
| JP2002537810A (ja) * | 1999-03-01 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトセルピンタンパク質 |
| WO2000051624A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Methods and compositions useful in inhibiting apoptosis |
| WO2000052034A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| US6849605B1 (en) | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| AU3864000A (en) | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses |
| US6489308B1 (en) | 1999-03-05 | 2002-12-03 | Trustees Of University Of Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions |
| US6174859B1 (en) | 1999-04-06 | 2001-01-16 | J & D Sciences, Inc. | Method of treatment |
| EP1200124B1 (en) | 1999-07-13 | 2008-09-10 | Bolder Biotechnology, Inc. | Erythropoietin-immunoglobulin fusion proteins |
| AU1101501A (en) | 1999-10-27 | 2001-05-08 | K-Quay Enterprises, Llc | Methods and compositions for treatment of keratoconus using protease inhibitors |
| JP2003515325A (ja) | 1999-12-01 | 2003-05-07 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体 |
| US6955845B1 (en) | 2000-06-30 | 2005-10-18 | Owens Corning Fiberglas Technology, Inc. | Acoustical and thermal insulator |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| KR20030070092A (ko) | 2001-01-04 | 2003-08-27 | 바스큘라 바이오제닉스 리미티드 | 죽상경화증을 예방 및 치료하기 위한 플라크 관련 분자를함유하는 조성물 및 이 분자를 이용하는 방법 |
| CN1547586A (zh) | 2001-02-23 | 2004-11-17 | ���鹫˾ | 提高的活性蛋白回收率 |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US6957148B2 (en) | 2001-05-21 | 2005-10-18 | The Board Of Regents, University Of Texas System | Next-nearest-neighbor sequence determinants of antisense DNA |
| US7304033B2 (en) | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| IL159015A0 (en) | 2001-05-25 | 2004-05-12 | Genset Sa | Polypeptides, their preparation and use |
| US7001884B2 (en) | 2001-06-18 | 2006-02-21 | Regents Of The University Of Michigan | Eglin c based drugs for treatment of disease |
| US7393539B2 (en) | 2001-06-22 | 2008-07-01 | Health Protection Agency | Mycobacterial antigens expressed under low oxygen tension |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US6924267B2 (en) | 2001-09-18 | 2005-08-02 | Suomen Punainen Risti Veripalvelu | Methods and active substances for protecting organs |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| WO2003059935A2 (en) | 2001-12-21 | 2003-07-24 | Immunex Corporation | Methods for purifying protein |
| CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| AU2003245325A1 (en) | 2002-05-23 | 2003-12-12 | Chiron Corporation | Substituted quinazolinone compounds |
| AU2003252178A1 (en) | 2002-07-25 | 2004-02-16 | Advances Life Sciences, Inc. | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals |
| WO2004052236A2 (en) | 2002-12-06 | 2004-06-24 | Arriva Pharmaceuticals, Inc. | Methods and compositions for treatment of otitis media |
| US20040220242A1 (en) | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| DK1694342T3 (da) | 2003-11-12 | 2021-02-08 | Univ Pennsylvania | Fremgangsmåder til anvendelse af gelsolin til behandling eller forebyggelse af bakteriel sepsis |
| EP1682584B1 (en) * | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| KR101300929B1 (ko) | 2004-05-12 | 2013-08-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
| ES2516690T5 (es) * | 2005-06-07 | 2017-11-21 | The Regents Of The University Of Colorado, A Body Corporate | Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos |
| US8715649B2 (en) * | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| WO2009005877A2 (en) | 2007-04-20 | 2009-01-08 | Regents Of The University Of Colorado | Alpha-i antitrypsin having no significant serine protease inhibitor activity |
| WO2007079312A2 (en) | 2005-12-02 | 2007-07-12 | Regents Of The University Of Colorado | Compositions and methods for treating actin-mediated medical conditions |
| US20070280922A1 (en) | 2006-06-06 | 2007-12-06 | Zoltan Kiss Consulting | Combinations of human proteins to enhance viability of stem cells and progenitor cells |
| ES2651268T3 (es) | 2006-09-12 | 2018-01-25 | Beth Israel Deaconess Medical Center, Inc. | Composiciones que contienen alfa-1-antitripsina y métodos para su uso |
| CL2007003411A1 (es) * | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| US20080199467A1 (en) | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
| WO2008138017A2 (en) * | 2007-05-08 | 2008-11-13 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| WO2009012600A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
| KR100992526B1 (ko) * | 2007-11-21 | 2010-11-05 | 한국과학기술연구원 | 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법 |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| RU2503688C2 (ru) | 2009-04-22 | 2014-01-10 | Алтеоген, Инк | Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением |
| WO2011102845A1 (en) | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| WO2011109768A2 (en) | 2010-03-04 | 2011-09-09 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for modulating cardiac conditions |
| US20120225813A1 (en) | 2010-06-11 | 2012-09-06 | Lewis Eli C | Compositions, methods and uses for treatment of type 1 diabetes |
| KR102103476B1 (ko) * | 2011-06-24 | 2020-04-23 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| KR20140068861A (ko) | 2011-06-28 | 2014-06-09 | 인히브릭스 엘엘씨 | Wap 도메인 융합 폴리펩티드 및 이의 이용 방법 |
| EP3569243A1 (en) * | 2011-06-28 | 2019-11-20 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
| WO2013106589A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
-
2012
- 2012-06-22 KR KR1020147001915A patent/KR102103476B1/ko active Active
- 2012-06-22 EP EP19202264.8A patent/EP3628327A1/en not_active Withdrawn
- 2012-06-22 WO PCT/US2012/043869 patent/WO2012178102A2/en not_active Ceased
- 2012-06-22 AU AU2012272636A patent/AU2012272636A1/en not_active Abandoned
- 2012-06-22 EP EP12802540.0A patent/EP2723370A4/en not_active Ceased
- 2012-06-22 CA CA2839917A patent/CA2839917A1/en not_active Abandoned
- 2012-06-22 KR KR1020207011059A patent/KR20200044138A/ko not_active Ceased
- 2012-06-22 US US14/125,135 patent/US9938353B2/en active Active
- 2012-06-22 JP JP2014517226A patent/JP6216921B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-28 AU AU2016202734A patent/AU2016202734A1/en not_active Abandoned
- 2016-12-20 JP JP2016246746A patent/JP2017079769A/ja not_active Withdrawn
-
2018
- 2018-01-24 AU AU2018200571A patent/AU2018200571C1/en not_active Ceased
- 2018-03-14 US US15/921,469 patent/US10450384B2/en active Active
-
2019
- 2019-01-28 JP JP2019012303A patent/JP2019058197A/ja active Pending
- 2019-09-16 US US16/572,371 patent/US20200109215A1/en not_active Abandoned
- 2019-10-29 AU AU2019257412A patent/AU2019257412B2/en not_active Ceased
-
2020
- 2020-07-14 JP JP2020120557A patent/JP2020171316A/ja active Pending
-
2021
- 2021-09-10 US US17/471,466 patent/US12030958B2/en active Active
-
2024
- 2024-05-07 US US18/656,832 patent/US20250101131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020171316A5 (cg-RX-API-DMAC7.html) | ||
| JP2019058197A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210357T1 (hr) | Stabilna i topljiva protutijela koja inhibiraju tnf | |
| JP2007515432A5 (cg-RX-API-DMAC7.html) | ||
| ES2348829T3 (es) | Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina. | |
| ES2817052T3 (es) | Derivados de imidazopiridazina como moduladores de la actividad de TNF | |
| JP2024138024A5 (cg-RX-API-DMAC7.html) | ||
| RU2010107994A (ru) | Композиции и способы кристаллизации антител | |
| JP2021507690A5 (cg-RX-API-DMAC7.html) | ||
| JP2009534421A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521458A5 (cg-RX-API-DMAC7.html) | ||
| JP2018525379A5 (cg-RX-API-DMAC7.html) | ||
| JP2012510821A5 (cg-RX-API-DMAC7.html) | ||
| RU2012111597A (ru) | Новые il-17-связывющие соединения и их медицинское применение | |
| JP2018515531A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0718750A2 (pt) | Derivados de quinclidina de ácido (hetero) arilciclo-heptanocarboxílico como antagonistas de receptor muscarínico. | |
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| BRPI1009576B1 (pt) | anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13. | |
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| BR112020024148A2 (pt) | Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2 | |
| RU2017118325A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| JP2011518857A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537888A5 (cg-RX-API-DMAC7.html) | ||
| JP2021073256A5 (cg-RX-API-DMAC7.html) | ||
| CN102089304A (zh) | 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物 |